3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
13
Plasma cell
3
Gastrointestinal
3
Tumor-Agnostic
2
Thoracic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Radiotherapy
215
Cyclophosphamide
210
Doxorubicin
207
Temozolomide
181
Ifosfamide
121
Filgrastim
111
Etoposide
101
Imatinib Mesylate
99
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Irinotecan
79
Magnetic Resonance Spectroscopy
78
pembrolizumab
75
Radiation
66
Carboplatin
65
pazopanib
60
Methotrexate
60
Nivolumab
58
Cisplatin
58
fludarabine phosphate
56
Peripheral Blood Stem Cell Transplantation
56
Specimen Handling
53
Docetaxel
50
Busulfan
48
Trabectedin
47
Biopsy
47
Melphalan
46
Surgical Procedures, Operative
44
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rivaroxaban
×
Sarcoma
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled